Wednesday, 27 March 2019

08:00

Conference Registration, Materials Pick-Up, Morning Coffee and Breakfast Pastries


Session Title: Conference Plenary Session -- Emerging Themes in Circulating Biomarkers and Liquid Biopsies


Plenary Session Chairperson: Lucia R. Languino, Ph.D., Professor of Cancer Biology, Thomas Jefferson University

09:00

Jennifer JonesKeynote Presentation

Mt-SEA Pipeline: High Throughput Flow Cytometric Analysis of Exosomes in Clinical Biofluids
Jennifer Jones, Staff Clinician, Molecular Immunogenetics & Vaccine Research Section, National Cancer Institute (NCI), United States of America

Because Extracellular Vesicles (EVs) carry surface receptors that are characteristic of their cells of origin, EVs have tremendous potential as non-invasive biomarkers for diagnosis, risk-stratification, treatment selection, and treatment monitoring. We developed a first-in-class pipeline to characterize EV heterogeneity and provide high-sensitivity quantification of informative EVs in biofluids before, during, and after treatment. By combining multiplex assays with high-resolution, single EV flow cytometric methods together into a Mutiplex-to-Single EV Analysis (Mt-SEA) pipeline, we are able to characterize a broad range of relevant EV subsets, while also accurately measuring the concentration of specific EV populations.  Detection of tumor-associated EVs and detection of EV repertoire changes during treatment paves the way to future evaluation of EVs as as biomarkers for use in personalized, adaptive therapies.

09:30

Erkki RuoslahtiKeynote Presentation

Disease-Specific Vascular Markers for Cancer, Atherosclerosis and Brain Diseases
Erkki Ruoslahti, Distinguished Professor and Former President, Sanford Burnham Prebys Medical Discovery Institute, United States of America

We study peptides that home to specific targets in the body. We discover the homing peptides by screening phage libraries for peptides that direct homing of phages to the target tissue in vivo. The homing peptides, which usually bind to receptors in the vessels of the target tissue, can be used to selectively deliver diagnostic probes and drugs to the target. The latest development is the discovery of tumor-penetrating peptides. These peptides activate an endocytic bulk transport pathway we have dubbed the CendR pathway, which can enhance the exit from blood and tissue penetration co-administered compounds even without chemical coupling to the peptide (Ruoslahti, Adv Mater. (2012) 24 3747). We have also identified peptides specific for atherosclerotic plaques, accumulate at the site of a brain injury or recognize the blood vessels in Alzheimer’s disease brain. Our homing frequency have an intrinsic biological active I the disease they target. Examples of the peptide discovery process from initial screening to clinical trials will be given.

10:00

Coffee Break and Networking in the Exhibit Hall

10:45

Steve SoperKeynote Presentation

Precision Medicine Using Liquid Biopsies: A New Paradigm for Managing Cancer Diseases
Steve Soper, Foundation Distinguished Professor, Director, Center of BioModular Multi-scale System for Precision Medicine, The University of Kansas, Adjunct Professor, Ulsan National Institute of Science & Technology, United States of America

Precision medicine seeks to match patients to appropriate therapies that optimize clinical outcome from molecular signatures of their disease. These molecular signatures can be secured from circulating markers found in blood (i.e., liquid biopsies). The marker types include circulating tumor cells (CTCs), cell-free DNA (cfDNA), and nanoscale vesicles (exosomes). Unfortunately, many disease-associated blood markers are a vast minority in a mixed population making them difficult to analyze due to deficiencies in current technologies used for their isolation. To address this deficiency, we are generating innovative microfluidic tools for selecting circulating markers from whole blood and determining the presence/absence of disease-specific molecular signatures secured from the liquid biopsy markers to guide therapy for a patient. The microfluidics can process whole blood (=1 mL) and search for CTCs, cfDNA, or exosomes and make them available for downstream molecular processing. The microfluidics are made in plastics via injection molding, making them particularly attractive for clinical implementation, which demands low-cost disposables. In this keynote address, I will discuss our microfluidic platforms for CTC, cfDNA, and exosome isolation. The exosome chip consists of 1.4 million pillars that contain surface-immobilized antibodies directed against antigens from cancer cells that are epithelial based (EpCAM) and those with a mesenchymal phenotype (fibrobast activation protein alpha, FAPa). I will then talk extensively about our exosome isolation chip, and its use in several clinical examples and securing molecular information from the affinity-selected exosomes.

11:15

Lucia LanguinoConference Chair

Exosomes: Novel Opportunities for the Diagnosis and Therapy of Cancer
Lucia Languino, Professor of Cancer Biology, Thomas Jefferson University, United States of America

11:45

Yves A. DeClerckKeynote Presentation

Tumor-derived Exosomes Contribute to a Pro-inflammatory Tumor Microenvironment through the Stimulation of Chemokines and Cytokines in Mesenchymal Stromal Cells and Macrophages
Yves A. DeClerck, Professor of Pediatrics and Biochemistry & Molecular Medicine, Children’s Hospital Los Angeles, University of Southern California, United States of America

Exosomes are members of a large family of extracellular vesicles involved in cell-cell communication that play important regulatory functions in physiological and pathological conditions. Using neuroblastoma (NB), the second most common solid tumor in children and a cancer that is highly metastatic to the bone marrow and the liver as a model, we show that NB-derived exosomes contribute to the stimulation of several protumorigenic cytokines and chemokines (IL-6, IL-8, MCP-1, VEGF) by mesenchymal stromal cells (MSC) and macrophages via ERK1/2 activation.  In vivo NB-derived exosomes are also preferentially captured by macrophages at the site of metastasis (bone marrow and liver).  Altogether these cytokines promotes the proliferation of tumor cells, their resistance to chemotherapy and immune escape via STAT3 and ERK1/2 activation.

12:15

Networking Lunch in the Exhibit Hall and Poster Viewing


Session Title: Intercellular Communication Mediated by Exosomes/EVs - An Emerging Class of Circulating Biomarkers

13:30

Cancer–Host Crosstalk Through Exosomal miRNA
Shizhen Emily Wang, Associate Professor, Department of Pathology, University of California, San Diego, United States of America

Extracellular microRNAs (miRNAs) that can be detected in the circulation are novel mediators of intercellular communication and are considered emerging biomarkers for human diseases. Using cell-secreted extracellular vesicles (e.g., exosomes) as vehicles, miRNAs secreted by cancer cells can travel to and enter various types of niche cells in primary and pre-metastatic tumor microenvironments. Upon entering niche cells, miRNAs regulate gene expression to prepare the niche for cancer progression. Our lab focuses on defining the roles of breast cancer secreted miRNAs in adapting local and distal niche cells and tissues in cancer progression and metastasis. Through de novo sequencing and PCR of circulating small RNAs in the sera of breast cancer patients we identified circulating miRNAs as biomarkers for cancer progression to metastatic disease. Subsequent mechanistic studies revealed important functions of breast cancer secreted miRNAs in various aspects of cellular behaviors. Our findings reveal (1) vascular leakiness and enhanced metastasis caused by cancer-secreted miR-105, which downregulates endothelial tight junctions; (2) miR-105-induced metabolic plasticity in cancer-associated fibroblasts to convert cancer-produced metabolic wastes (e.g., lactate and ammonia) into energy-rich metabolites to re-enter cancer bioenergetics; (3) suppressed glucose utilization by lung fibroblasts and astrocytes in favor of glucose uptake by metastasized cancer cells mediated by cancer-secreted miR-122.

14:00

Utkan DemirciKeynote Presentation

Chemistry-Free Microfluidic Technologies to Sort Cells for Health and Disease
Utkan Demirci, Professor, Stanford University School of Medicine, United States of America

Micro- and nano-scale technologies can have a significant impact on medicine and biology in the areas of cell manipulation, diagnostics and monitoring. At the convergence of new technologies and biology, our research is centered on enabling solutions to real world problems at the clinical level. Emerging nano-scale and microfluidic technologies integrated with biology offer innovative possibilities for creating intelligent and mobile medical lab-chip devices that could transform diagnostics and monitoring, tissue engineering and regenerative medicine. In this talk, we will first present an overview of our laboratory's work in the areas focused on applications in magnetic levitation methods for assembling cells and chemistry free sorting of rare cells from whole blood. Cells consist of micro- and nano-scale components and materials that contribute to their fundamental magnetic and density signatures. Previous studies have claimed that magnetic levitation can only be used to measure density signatures of non-living materials. Here, we demonstrate that both eukaryotic and prokaryotic cells can be levitated and that each cell has a unique levitation profile. Furthermore, our levitation platform uniquely enables ultrasensitive density measurements, imaging, and profiling of cells in real-time at single-cell resolution. This method has broad applications, such as the label-free identification and sorting of CTCs and CTM with broad applications in drug screening in personalized medicine. Second, we will present some of our efforts on developing new tools to isolate extracellular vesicles from blood, urine and cell cultures. I will also share some of the clinical implications of these technologies indicating the broader potential that chemistry-free and label-free microfluidic-based technologies have in medicine.

14:30

Izon Science US LTDA Straightforward, Automated and Standardizable Approach to Purifying and Characterizing the Biophysical Properties of EVs; Size, Concentration and Surface Charge
Shayne Harrel, Chief Scientist-Americas, Izon Science US LTD

The ever increasing discovery of the role of extracellular vesicles (EVs) in a wide range of biological roles and functions has lead them to be realized as a prime candidate for the next generation platform of medical diagnostics and therapeutics.  As such, an accurate, repeatable and standardizable approach to measuring the biophysical properties of these particles such as concentration, particle size and surface charge and correlating these biophysical properties to biological role and function is desperately required.  This presentation will focus on recent developments at Izon Science which have created an integrated methodology for the straightforward, automated purification of EVs and subsequent characterization of their biophysical properties.

15:00

Modulation of Extracellular Vesicle Release and Content in SCC Cells
My Mahoney, Professor and Vice Chair, Thomas Jefferson University, United States of America

Emerging as critical in the pathobiology of cancer are nanosized extracellular membrane vesicles (EVs) secreted by tumor cells into the blood and other bodily fluids carrying molecular constituents to modulate local and distant tumor microenvironment. EVs can be taken up by recipient cells and can modulate diverse biological processes including cell polarity and tissue morphogenesis and represent novel and valuable circulating biomarkers for tumor prognosis and diagnosis. Thus, defining factors that affect the release or modify the content of EVs is critical to our understanding of not only normal tissue development but also malignant transformation and progression. We have shown that the cadherin desmoglein 2 (Dsg2), an important regulator of growth and survival signaling pathways, drives tumorigenesis in experimental models, and clinical samples confirm that Dsg2 is indeed overexpressed in those cancers. We observed that Dsg2 is enriched in EVs derived from SCC cells and patient sera. Dsg2 modulates EV release and mitogenic content including EGFR and c-Src. Dsg2-labeled EVs are taken up by dermal fibroblasts, activating Erk1/2 and Akt signaling and promoting cell proliferation. Our work thus far defines a mechanism by which cancer cells can modulate the tumor microenvironment, a step critical for tumor progression.

15:30

Coffee Break and Networking in the Exhibit Hall

16:00

NanoFCMNano-Flow Cytometry: Next-Generation Platform for Comprehensive EV Analysis
Dimitri Aubert, VP Sales and Marketing, Managing Director Europe, NanoFCM

Though of great importance, sizing and molecular profiling of individual extracellular vesicles (EVs) are technically challenging due to their nanoscale particle size, minute quantity of analytes, and overall heterogeneity. NanoFCM has developed Nano-Flow Cytometry (nFCM), a technology that allows light scattering and fluorescence detection of single EVs down to 40 nm. nFCM-based approach for quantitative multiparameter analysis of EVs, which is highly desirable to decipher their biological functions and promote the development of EV-based liquid biopsy and therapeutics.

16:30

A Novel Extracellular Vesicle Isolation Method Used to Discover Urine Liver Disease Candidate Biomarkers
Shannon Pendergrast, Chief Scientific Officer, Ymir Genomics, United States of America

Hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide, with increasing incidence, and is the third most common cause of cancer death. The clinical management of patients suffering from HCC, despite the fact that at-risk populations are well defined, is not satisfactory. This is mainly due to the unavailability of current diagnostics to predict and monitor the disease. OHSU and Ymir Genomics LLC have teamed up to develop a high-compliance urinary diagnostic for liver diseases, including HCC. We have developed a new method for the rapid and effective isolation of urine extracellular vesicles (EVs) and integrated that into Mass Spectrometry and miRNA array workflows. We have applied  the workflow to 3 groups of 20 urine samples each from 1) healthy controls, 2) patients with cirrhosis, and 3) and cirrhotic patients with untreated HCC. Mass Spectrometry data shows that this protocol is capable of identifying over 2500 proteins from only 2 mls of urine; far less sample than some previously reported urine EV proteomics studies. Our protocol also yields sensitive miRNA detection from the Firefly miRNA array. Preliminary data establishes proof-of-concept by identifying multiple liver-selective and known liver disease biomarkers in urine EV preps. Several candidate protein and miRNA biomarkers that are potentially capable of distinguishing disease from healthy groups have also been identified. The methods developed in this study are suitable for a larger longitudinal study, as they are already compatible with standard clinical chemistry laboratory assay requirements.  Hopefully, candidates biomarkers identified in this study will provide clinicians with powerful weapons in the fight against HCC.

17:00

Particle Metrix GmbHEV Biomarker Detection using Particle Metrix ZetaView® Instruments and Fluorescent Nanoparticle Tracking Analysis (F-NTA)
Sven Rudolf Kreutel, General Sales Manager, Particle Metrix GmbH

17:30

Low Coverage, Genome-Wide Sequencing of Cell-Free DNA Enables the Monitoring of Response to Immunotherapy in Cancer Patients
Taylor Jensen, Director, Research and Development, Sequenom (a LabCorp Company), United States of America

Inhibitors of the PD-1/PD-L1/CTLA4 immune checkpoint pathway have revolutionized cancer treatment with a subset of patients showing durable responses; however, challenges remain in the development of biomarkers to predict or monitor response to these therapies.  The use of cell-free DNA (cfDNA) isolated from plasma, or liquid biopsy, provides a promising method for monitoring response.  In contrast to methods that use ultra-deep (>30,000X) targeted sequencing, we will describe a recently completed a proof-of-concept study using low-coverage (~0.3X), genome-wide sequencing of cfDNA to detect tumor-specific copy number alterations.  As part of this study, we have developed a novel metric, the Genome Instability Number (GIN), to monitor response to these drugs throughout treatment.  In a series of case studies, we will describe how the GIN can be used to discriminate clinical response from progression, differentiate progression from pseudoprogression and identify hyperprogressive disease.  In addition, we have utilized this metric to provide evidence for a delayed pharmacokinetic response for checkpoint inhibitors relative to targeted therapies.

18:00

Networking Reception with Beer and Wine in the Exhibit Hall

19:00

Close of Day 1 of the Conference.

19:30

Start of Exosomes/Extracellular Vesicles (EV) Training Course [Separate Registration Required to Attend this Training Course]

Thursday, 28 March 2019

08:00

Morning Coffee Break and Breakfast Pastries Served in the Exhibit Hall


Session Title: Microfluidics and NGS Technologies for Circulating Biomarkers Analysis

08:30

Silicon Chip Nanofluidics for Extracellular Vesicle Enrichment
Benjamin H. Wunsch, Research Staff Member, T.J. Watson Research Center, IBM, United States of America

Silicon lithography provides a high resolution and scalable route to fabricating nanofluidic structures on a chip. We describe a silicon chip based on the nanoscale deterministic lateral displacement (nanoDLD), for enriching extracellular vesicles from biological fluids based on size. We report on our pilot efforts to use high- throughput extraction of EVs from urine and serum to aid in the identification of cancer-specific biomarkers.

09:00

Hsian-Rong TsengKeynote Presentation

NanoVelcro Rare-Cell Assays for Detection and Characterization of Circulating Tumor Cells
Hsian-Rong Tseng, Professor, Crump Institute for Molecular Imaging, California NanoSystems Institute, University of California-Los Angeles, United States of America

Circulating tumor cells (CTCs) are cancer cells shredded from either a primary tumor or a metastatic site and circulate in the blood as the potential cellular origin of metastasis. By detecting and analyzing CTCs, we will be able to noninvasively monitor disease progression in individual cancer patients and obtain insightful information for assessing disease status, thus realizing the concept of “tumor liquid biopsy”. Over the past decade, our research team at UCLA pioneered a unique concept of “NanoVelcro” cell-affinity substrates, in which CTC capture agent-coated nanostructured substrates were utilized to immobilize CTCs with remarkable efficiency. Five generations of NanoVelcro CTC assays have been developed over the past decade for a variety of clinical utilities, including CTC enumeration for prognosis and staging, single-CTC mutational analysis for tracking tumor origin, and CTC-based molecular analysis for treatment monitoring.  In this presentation, I will summarize the development of the new generations of NanoVelcro CTC assays and the clinical applications of these new diagnostic devices.

09:30

Michael HellerKeynote Presentation

Rapid Simultaneous Isolation and Detection of Exosome/EV and cfDNA Biomarkers from Cancer Patient Blood Samples
Michael Heller, Distinguished Scientist - Knight Cancer Institute at Oregon Health & Science University (OHSU), Center for Cancer Early Detection and Research (CEDAR); Professor, University of California-San Diego, United States of America

Multi-omic approaches using different types of biomarkers will be a viable strategy for liquid biopsy diagnostics and early cancer detection. A novel electrokinetic sample to answer device (ACE chip, Biological Dynamics, San Diego, CA) was used to isolate exosomes, extracellular vesicles (EVs) and cell free (cf) DNA from 20-50 µL of cancer patient plasma samples. Fluorescent detection of the cf-DNA and immunostaining for exosome/EV protein biomarkers could then be rapidly carried out directly on-chip. Subsequently, cf-DNA and exosome/EV entrapped RNA could be eluted from the ACE chip, whereupon PCR and sequencing analysis is conducted to identify cancer-related point mutations. Our results show correlation of immunofluorescent detection of exosome/EV glypican-1 and cf-DNA KRAS mutations (G12V, G12D) determined by digital PCR for a number of patient samples from pancreatic and colorectal cancers, where lung cancer patient samples were used as a negative control. This provides further advancement towards integrating multi-omics analysis as a single, on-chip platform, with an ultimate goal of providing seamless sample-to-answer point-of-care liquid biopsy diagnostics.

10:00

Lydia SohnKeynote Presentation

mechano- and visco-NPS: An Electronic Method to Measure the Mechanical Properties of Cells
Lydia Sohn, Professor of Mechanical Engineering, University of California-Berkeley, United States of America

We have developed an efficient, label-free method of screening cells for their phenotypic profile, which we call Node-Pore Sensing (NPS).  NPS involves measuring the modulated current pulse caused by a cell transiting a microfluidic channel that has been segmented by a series of inserted nodes.  Previously, we showed that when segments between the nodes are functionalized with different antibodies corresponding to distinct cell-surface antigens, immunophenotyping can be achieved.  In this talk, I will show how we have significantly advanced NPS by simply inserting between two nodes a “contraction” channel through which cells can squeeze.  “Mechano-NPS”, as we now call our method, can simultaneously measure a cell’s size, resistance to deformation, transverse deformation, and ability to recover from deformation.  As I will show, mechano-NPS can distinguish malignant from non-malignant epithelial cells and discriminate between sub-lineages and, excitingly, chronological age groups of primary human mammary epithelial cells.  Moreover, mechano-NPS can track malignant progression.  By replacing the contraction channel with one that is sinusoidal in shape, we can measure the viscoelastic properties (elasticity and viscosity) of cells.  I will show how “visco-NPS” can quantify the mechanical transitions of cells as they traverse the cell cycle or are initiated into an epithelial-mesenchymal transition.

10:30

Coffee Break and Networking in the Exhibit Hall

12:00

Networking Lunch in the Exhibit Hall and Poster Viewing

12:30

Afternoon Session Presentations in the EV Summit Track

17:30

Industry Panel Discussion Focusing on Circulating Biomarkers & Liquid Biopsy

18:15

Close of Day 2 of the Conference Track

Friday, 29 March 2019

08:30

Morning Coffee and Breakfast Pastries Served in the Exhibit Hall


Session Title: Late-Breaking Session

09:00

The Unique Challenges and Opportunities of Circulating Tumor DNA
Alex Lovejoy, Principal Scientist, Roche Sequencing Solutions, United States of America

Despite the promise of circulating tumor DNA (ctDNA) as a minimally invasive biomarker, the detection and quantification of small amounts of ctDNA in a plasma sample is a difficult problem.  Limited input molecules, background noise, and cost of sequencing are all challenges that hinder the implementation of assays for ctDNA detection.  This talk will describe these difficulties in detail, as well as the development of the Roche AVENIO ctDNA Analysis Kits (Research Use Only), which have been specifically designed to overcome these challenges.

09:30

exRNA Biomarkers: Challenges in Methodology
Srimeenakshi Srinivasan, Research Fellow, University of California, San Diego, United States of America

The study of exRNAs and their roles in biological functions and potential biomarkers require robust and reproducible methods for quantification of exRNAs in biofluids, a task that is made more challenging by multiple sources of technical and biological variability. A number of factors including the variety of cells/tissues from which the exRNAs are produced, the low concentrations of exRNAs in the biofluids, the presence nucleases and association with multiple different extracellular compartments impact the reproducibility of exRNA measurements, and are likely a significant reason that the field has encountered difficulties with validation of findings both within and among different research groups. Here we compare various exRNA isolation methods used on standardized samples in multiple laboratories and evaluate their performance using qRT-PCR and small RNA sequencing. The results show that different methods enrich for different subsets of exRNAs depending on their association with extracellular carriers and the reproducibility of each method varies widely. Thus selection of the RNA isolation method is a critical consideration to be taken into account when planning a study to identify exRNA biomarkers.

10:00

Identification and Characterization of Circulating Long Non-Coding RNAs and HPV16/18 Cell-Free DNA as Cancer Biomarkers from Serum of Cervical Cancer Patients
Tawin Lempridee, Researcher, National Nanotechnology Center (NANOTEC), National Science and Technology Development Agency, Thailand

Circulating lncRNAs and HPV16/18 E7 ctDNA may be used as cancer biomarkers for developing a blood-based cervical cancer screening test.

10:30

Probing the Extracellular RNA Landscape in Neurodegenerative Disease
Elizabeth Hutchins, Computational Scientist, The Translational Genomics Research Institute (TGen), United States of America

Molecular information from biofluids can be used to monitor and understand disease progression, identify biomarkers, develop assays, and for therapeutic discovery. The minimally invasive nature for collecting extracellular information from biofluids allows for frequent sampling, with the potential to closely monitor pathophysiological mechanisms of traumatic injury and disease. We have isolated and identified many types of extracellular RNA from biofluids using high-throughput RNA sequencing, including microRNA, protein coding RNA, lncRNA, and circRNA.

11:00

Tumor-derived Extracellular Vesicles Require ß1 Integrins to Promote Anchorage-Independent Growth
Rachel DeRita, Researcher, Thomas Jefferson University, United States of America

The ß1 integrins, known to promote cancer progression, are abundant in extracellular vesicles (EVs).  We investigated whether prostate cancer (PrCa) EVs affect anchorage-independent growth and whether ß1 integrins are required for this effect.  Specifically using a cell line-based genetic rescue and an in vivo PrCa model, we show that gradient purified small EVs (sEVs) from either cancer cells or blood from tumor-bearing TRAMP mice promote anchorage-independent growth of PrCa cells.  In contrast, sEVs from cultured PrCa cells harboring a shRNA to ß1, from wild-type mice or from TRAMP mice carrying a ß1 conditional ablation in the prostatic epithelium (ß1pc-/-), do not.  We find that sEVs, from cancer cells or TRAMP blood, are functional and co-express ß1 and sEV markers; in contrast, sEVs from ß1pc-/- /TRAMP or wild-type mice lack ß1 and sEV markers.  Our results demonstrate that ß1 integrins in tumor-derived sEVs are required for stimulation of anchorage-independent growth.

11:30

Extracellular Vesicles From Prostate Cancer Cells Promote Angiogenesis Through alphavß6 Integrin
Shiv Ram Krishn, Post-doctoral Fellow, Thomas Jefferson University, United States of America

Increased angiogenesis in prostate tumors has been shown to be promoted by cancer cells, but the underlying mechanisms are not completely understood.  Prostate cancer (PrCa) cells continuously release extracellular vesicles (EV) of endosomal origin, to mediate unique crosstalk with other cells in the tumor microenvironment by direct transfer of vesicular cargo.  Our group has shown expression of alphav-beta6 integrin (alphavß6), which is an epithelial-specific integrin, in human PrCa cell-derived EV.  We hypothesized that extracellular vesicles-associated alphavß6 (EV-alphavß6) shed by PrCa cells may impact the endothelial cells in the prostate tumor microenvironment and thus angiogenesis.  Here in, we demonstrate that EV-alphavß6 is efficiently transferred to alphavß6-negative recipient human microvascular endothelial cells (HMEC1).  We also demonstrate the intracellular localization of ß6-GFP transferred via PrCa cell-derived EVs.  De novo alphavß6 expression in HMEC1 is not a result of a change in mRNA levels but is a consequence of EV-mediated transfer of alphavß6 from PrCa cells to HMEC1.  Incubation of HMEC1 with purified EV from PC3 cells, transfected with shRNA to ß6, results in a significant reduction in viability and motility of HMEC1.  Our results also demonstrate that EV-alphavß6 significantly augments tube formation of HMEC1.  At the molecular level, our results demonstrate that transfer of PrCa cell-derived EV-alphavß6 to HMEC1 causes down-regulation of STAT1, a molecule known to negatively regulate angiogenesis.  Overall, our study suggests that EV-mediated transfer of alphavß6 from PrCa cells to endothelial cells may regulate angiogenesis during PrCa progression.

12:00

Close of Conference